Roche Opens Institute of Human Biology in Basel with CHF 1.4 Billion Investment to Revolutionize Drug Discovery
核心洞察
Roche inaugurated its new Institute of Human Biology (搜索) in Basel as part of a CHF 1.4 billion site investment, reinforcing Switzerland's position as a global life sciences hub.
The facility will house up to 250 researchers developing advanced human model systems including organoids (搜索), organ-on-chip (搜索) technologies, and AI-powered computational models to replicate human disease biology.
The institute aims to overcome limitations of traditional research models by enabling more predictive and efficient drug development, potentially accelerating the translation of discoveries into patient treatments.
Roche has officially opened its Institute of Human Biology (搜索) (IHB) in Basel, Switzerland, marking a transformative milestone in the company's drug discovery strategy. The new facility, housed in Building 92, represents part of a substantial CHF 1.4 billion investment in the Basel life sciences cluster and aims to revolutionize how new medicines are developed through advanced human model systems.
The institute will accommodate up to 250 researchers working at the intersection of human disease biology, computational biology, and translational bioengineering. By pioneering sophisticated human model systems, the facility is designed to overcome the limitations of traditional research approaches and accelerate the development of new therapeutics.
Advanced Human Model Systems Drive Innovation
The IHB leverages cutting-edge technologies to create unprecedented precision in disease modeling. Scientists at the facility will develop and utilize complex cultured tissue samples, organoids (搜索), microfluidic 'organ-on-chip (搜索)' technologies, and in silico modeling systems. These advanced models are designed to replicate human disease biology with greater accuracy than conventional research methods.
"By combining human organoid models with artificial intelligence (搜索), IHB has the potential to change how we discover and develop new medicines - making research and development more predictive and more efficient," said Thomas Schinecker, CEO of the Roche Group. "Together with our partners, we aim to bring innovative treatments to patients faster."
The integration of artificial intelligence (搜索) with biological systems represents a key differentiator for the institute. This combination is expected to enable more accurate predictions of treatment effectiveness and support earlier evaluation of therapeutic candidates.
Bridging Fundamental and Industry Sciences
Azad Bonni, Global Head and Director of the Institute of Human Biology (搜索), emphasized the facility's role in translational research. "By pioneering human model systems and better understanding human disease, we will move beyond the limitations of traditional research to predict if and how new treatments will work in people," Bonni stated.
The institute's design incorporates modular laboratories that allow for sustainable growth and foster interdisciplinary exchange. This collaborative environment is specifically engineered to bridge the gap between fundamental research discovery and industry application, facilitating rapid translation of groundbreaking science into patient-focused solutions.
Strategic Investment in Swiss Life Sciences
The new facility underscores Roche's long-term commitment to Switzerland as a global innovation hub. The company invests approximately CHF 3.5 billion annually in research and development in Switzerland, with the IHB representing a significant expansion of these capabilities.
Since 2016, Roche has invested approximately CHF 7 billion into its Swiss sites, with an additional CHF 33 billion invested in research and development in Switzerland over the same period. This brings the company's total investment in Switzerland to around CHF 41 billion over the past decade (2016 to 2025).
Reducing Reliance on Animal Testing
The human model systems developed at the IHB also have the potential to reduce reliance on animal testing by providing more relevant human-based alternatives. These simple representations of human tissues offer a more direct pathway to understanding how treatments will perform in human patients.
The Institute of Human Biology (搜索), founded in 2023, positions itself as a global leader in developing and engineering next-generation human model systems. The facility's multidisciplinary expertise and state-of-the-art infrastructure are designed to foster innovative collaborations and maintain Roche's position at the forefront of biomedical research.
The inauguration ceremony was attended by Federal Councillor Elisabeth Baume-Schneider, Head of the Federal Department of Home Affairs, highlighting the strategic importance of this investment to Switzerland's life sciences sector.